Frentizole

Overview

Frentizole, an FDA-approved immunosuppressant, is a Aβ-ABAD (binding alcohol dehydrogenase) interaction inhibitor with an IC 50 value of 200 μM. Frentizole is used in studies of diseases related to rheumatoid arthritis and systemic lupus erythematosus.

Application

Products | Products > Disease Areas > Alzheimer's Disease | Products > Disease Areas > Rheumatoid Arthritis | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Musculoskeletal and Skin Disease | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > Arthritis | Products > Signaling Pathways > Neuronal Signaling | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > Amyloid-β

Product Information

• Catalog No.: HY-15374
• CAS No.: 26130-02-9
• Molecular Formula: C15H13N3O2S
• Molecular Weight: 299.35
• Purity: 98.48%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: 1.25 mg/mL (4.18 mM); Clear solution; Need ultrasonic
• Availability: In-stock

Source

Original product source